ATE534664T1 - Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie - Google Patents

Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie

Info

Publication number: ATE534664T1
Authority: AT; Austria
Prior art keywords: therapy; agents; imaging; organ; fibrinolytic
Prior art date: 2004-05-24

Application number

AT05748704T

Other languages

English (en)

Inventor

Jocelyn Dupuis

Alain Fournier

Original Assignee

Inst Cardiologie Montreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-24

Filing date

2005-05-24

Publication date

2011-12-15

2005-05-24 Application filed by Inst Cardiologie Montreal filed Critical Inst Cardiologie Montreal

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE534664T1 publication Critical patent/ATE534664T1/de

Links

238000002560 therapeutic procedure Methods 0.000 title abstract 3
238000003384 imaging method Methods 0.000 title abstract 2
239000003527 fibrinolytic agent Substances 0.000 abstract 4
239000013543 active substance Substances 0.000 abstract 3
210000000056 organ Anatomy 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
210000004072 lung Anatomy 0.000 abstract 2
230000005298 paramagnetic effect Effects 0.000 abstract 2
230000002285 radioactive effect Effects 0.000 abstract 2
101800004616 Adrenomedullin Proteins 0.000 abstract 1
208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical class C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 1
239000003146 anticoagulant agent Substances 0.000 abstract 1
230000000740 bleeding effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000002595 magnetic resonance imaging Methods 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
230000005855 radiation Effects 0.000 abstract 1
230000002537 thrombolytic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

AT05748704T 2004-05-24 2005-05-24 Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie ATE534664T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57333404P	2004-05-24	2004-05-24
PCT/CA2005/000791 WO2005116065A1 (en)	2004-05-24	2005-05-24	Labelled adrenomedullin derivatives and their use for imaging and therapy

Publications (1)

Publication Number	Publication Date
ATE534664T1 true ATE534664T1 (de)	2011-12-15

Family

ID=35450839

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05748704T ATE534664T1 (de)	2004-05-24	2005-05-24	Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie

Country Status (6)

Country	Link
US (3)	US8703098B2 (de)
EP (1)	EP1749026B1 (de)
AT (1)	ATE534664T1 (de)
CA (1)	CA2567478C (de)
DK (1)	DK1749026T3 (de)
WO (1)	WO2005116065A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8475764B2 (en)	2004-05-24	2013-07-02	Institut De Cardiologie De Montreal	Labelled adrenomedullin derivatives and their use for imaging and therapy
US8703098B2 (en)	2004-05-24	2014-04-22	Institut De Cardiologie De Montreal	Labelled adrenomedullin derivatives and their use for imaging and therapy
WO2008138141A1 (en) *	2007-05-11	2008-11-20	Institut De Cardiologie De Montréal	Labelled adrenomedullin derivatives and their use for imaging and therapy.
JOP20190001B1 (ar)	2011-11-03	2022-03-15	Bayer Pharma AG	عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
US20180022780A1 (en)	2014-09-26	2018-01-25	Bayer Pharma Aktiengesellschaft	Stabilization adrenomedullin derivatives and use thereof
JP6924890B2 (ja) *	2017-07-05	2021-08-25	テレフレックスライフサイエンシーズアンリミテッドカンパニー	流体入力モジュール用のメカニカルユーザ制御要素
CA3143584A1 (en)	2019-06-18	2020-12-24	Bayer Aktiengesellschaft	Adrenomedullin-analogues for long-term stabilization and their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5443816A (en)	1990-08-08	1995-08-22	Rhomed Incorporated	Peptide-metal ion pharmaceutical preparation and method
WO1995022341A1 (en) *	1994-02-18	1995-08-24	Mallinckrodt Medical, Inc.	Labelled peptide compounds
US6027711A (en)	1995-06-07	2000-02-22	Rhomed Incorporated	Structurally determined metallo-constructs and applications
CA2222966C (en)	1995-06-07	2007-03-13	Immunomedics, Inc.	Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US6440421B1 (en)	1996-04-18	2002-08-27	Auchkland Uniservices Limited	Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
EP0975374B1 (de) *	1996-07-12	2007-12-05	Immunomedics, Inc.	Radiometall-bindende peptide analoge
US6083480A (en) *	1997-05-01	2000-07-04	Diatide, Inc.	Calcitonin receptor binding reagents
US6268474B1 (en)	1998-04-30	2001-07-31	Creighton University	Peptide antagonists of CGRP-receptor superfamily and methods of use
EP1545287B1 (de)	2002-10-04	2012-12-05	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES	Vasoregulierende verbindungen und anwendungsverfahren
DE60335743D1 (de)	2002-11-20	2011-02-24	Neuronova Ab	Verbindungen und verfahren zur erhöhung der neurogenese
US8475764B2 (en) *	2004-05-24	2013-07-02	Institut De Cardiologie De Montreal	Labelled adrenomedullin derivatives and their use for imaging and therapy
US8703098B2 (en) *	2004-05-24	2014-04-22	Institut De Cardiologie De Montreal	Labelled adrenomedullin derivatives and their use for imaging and therapy
JP2008538204A (ja)	2005-03-10	2008-10-16	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	安定化側鎖を含む放射性標識複合体キレート剤

2005
- 2005-05-24 US US11/597,315 patent/US8703098B2/en active Active
- 2005-05-24 WO PCT/CA2005/000791 patent/WO2005116065A1/en not_active Ceased
- 2005-05-24 EP EP05748704A patent/EP1749026B1/de not_active Expired - Lifetime
- 2005-05-24 CA CA2567478A patent/CA2567478C/en not_active Expired - Lifetime
- 2005-05-24 DK DK05748704.3T patent/DK1749026T3/da active
- 2005-05-24 AT AT05748704T patent/ATE534664T1/de active
2011
- 2011-07-07 US US13/067,914 patent/US9062123B2/en active Active
2015
- 2015-05-19 US US14/715,871 patent/US20150246145A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1749026B1 (de)	2011-11-23
US9062123B2 (en)	2015-06-23
WO2005116065A1 (en)	2005-12-08
EP1749026A4 (de)	2008-10-29
US20150246145A1 (en)	2015-09-03
EP1749026A1 (de)	2007-02-07
US20080274050A1 (en)	2008-11-06
CA2567478A1 (en)	2005-12-08
US8703098B2 (en)	2014-04-22
US20120082619A1 (en)	2012-04-05
DK1749026T3 (da)	2012-02-27
CA2567478C (en)	2014-04-01

Similar Documents

Publication	Publication Date	Title
Savitz et al.	2007	Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials
Swaminathan et al.	2007	New insights into nephrogenic systemic fibrosis
Shevtsov et al.	2019	Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70‐Positive Tumors for Multimodal Cancer Theranostics
ES2763899T3 (es)	2020-06-01	Método para predecir la eficacia de fármacos en un paciente
Hasenpusch et al.	2012	Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung
ATE411819T1 (de)	2008-11-15	Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
ATE349446T1 (de)	2007-01-15	Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
BRPI0507684B8 (pt)	2021-07-27	agentes de contraste para imagem de perfusão miocárdica
DE69819309D1 (de)	2003-12-04	Verabreichbare formulierugen und ihre anwendung in mri
IS4833A (is)	1998-08-26	Lífefnafræðilega virkjuð skuggaefni til myndgreiningar
FI953124A0 (fi)	1995-06-22	Vesipitoiset ruiskutettavat formuloinnit, joita voidaan käyttää röntgentutkimuksiin, jotka käsittävät jodattuja aromaattisia yhdisteitä, joita käytetään kontrastiväliaineina röntgentutkimuksiin
ATE534664T1 (de)	2011-12-15	Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
Schuller et al.	2007	No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome
DE69425572D1 (de)	2000-09-21	Iodierte paramagnetische chelaten, und deren verwendung als kontrastmittel
Karremann et al.	2009	Anaplastic ganglioglioma in children
Jalali et al.	2007	Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide
Arita et al.	2001	Intrasellar rhabdomyosarcoma: case report
Mudur	2006	Indian study sparks debate on the use of placebo in psychiatry trials
ATE450800T1 (de)	2009-12-15	Magnetstruktur für eine mri-vorrichtung und mri- vorrichtung
ATE347912T1 (de)	2007-01-15	Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik
He et al.	2011	Rhabdoid glioblastoma: case report and literature review
Nakazaki et al.	2013	Evaluation of mini-mental status examination score after gamma knife radiosurgery as the first radiation treatment for brain metastases
Lattanzio	2019	The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain
ATE546161T1 (de)	2012-03-15	Magnetische partikel zur verwendung in therapie und diagnostik
GB0517077D0 (en)	2005-09-28	Imaging agent